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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION
The European Community legislation lists nutritional substances that may be used for nutritional purposes in certain categories of foods as sources of certain nutrients.
The Commission has received a request for the evaluation of sodium hyaluronate added for nutritional purposes to food supplements. The relevant Community legislative measure is: 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Commission asks the European Food Safety Authority to provide a scientific opinion, based on its consideration of the safety and bioavailability of sodium hyaluronate added for nutritional purposes in food supplements.
Inability to assess the safety of sodium hyaluronate added for nutritional purposes as a source of sodium in food supplements and the bioavailability of sodium from this source, based on the supporting dossier STATEMENT
Introduction
Following a request from the European Commission to the European Food Safety Authority (EFSA), the Scientific Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to provide a scientific opinion on the safety of sodium hyaluronate added for nutritional purposes as a source of sodium in food supplements and on the bioavailability of sodium from this source.
Summary of the information provided
Sodium hyaluronate (CAS Registry Number 9067-32-7) is the sodium salt of hyaluronic acid, a linear polysaccharide composed of D-glucuronic acid and D-N-acetyl glucosamide linked by β-(1-3) glycoside bonds.
The petitioner describes three forms of sodium hyaluronate with molecular weights of <90000 Da, <200000 Da and >1000000 Da which are proposed to be used as a source of sodium in food supplements. A low molecular weight form of sodium hyaluronate with molecular weight of < 20000 Da is mentioned in the dossier but not further described.
Sodium hyaluronate is produced by means of fermentation of a vegetable-origin derived substrate by a selected strain (non-GMO) of Streptococcus zooepidermicus. The product of the fermentation is subsequently pasteurised and separated by filtration.
The product is described as a white powder, containing more than 95% hyaluronic acid; the sodium content is not explicitly stated. Limited chemical and microbiological specifications are provided. No methods of analysis of sodium hyaluronate in food are provided by the petitioner.
The petitioner intends to use sodium hyaluronate as an ingredient in capsules, however the proposed levels of use are not stated.
The petitioner provides limited information on toxicity (only cytotoxicity and acute toxicity data). No data are provided on the bioavailability of sodium from sodium hyaluronate. Other data provided by the petitioner are eye and skin irritation studies.
Assessment
The Panel notes that:
• The petitioner has not provided adequate information on the chemical characterisation of sodium hyaluronate.
• The petitioner has not provided any data on the bioavailability of sodium from sodium hyaluronate nor on the toxicity of sodium hyaluronate, apart from cytotoxicity, acute oral and dermal toxicity and eye and skin irritation studies.
